Would you use adagrasib in combination with cetuximab based on recently published article in NEJM for metastatic colon cancer with KRAS G12C mutation?  

The NCCN guidelines were recently updated to include KRAS G12C inhibitors (adagrasib/sotorasib) in combination with anti-EGFR antibodies (cetuximab/panitumumab) for KRAS G12C mutant metastatic colorectal cancer. The majority of patients with this alteration obtain clinical benefit from this combinat...

I think KRAS G12C targeting is very appropriate based on available data. The question over the near future is which one is based on the timeline of these trials. Later this month, CodeBreak300 will be presented in ESMO. Amgen already announced it met its primary endpoint (PFS over Lonsurf or regoraf...

Totally agree with Dr. @Yaeger that KRAS G12C targeted agent with an EGFR inhibitor is effective and quite well-tolerated for metastatic CRC patients with KRAS G12C mutation.One thing that puzzled me a little is that the phase II KRYSTAL-1 study demonstrated a combination of adagrasib with cetu...